Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Guanadrel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 5/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanadrel SCHEMBL1649864 | 1.00 | PABPC1 (0.40) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| Guanadrel SCHEMBL23858317 | 0.93 | PABPC1 (0.45) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| Guanadrel SCHEMBL41052 | 0.93 | PABPC1 (0.45) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| Guanadrel SCHEMBL23858327 | 0.91 | PABPC1 (0.44) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| Guanadrel SCHEMBL41051 | 0.75 | ADRA1D (0.40) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL9373459 | 0.71 | PABPC1 (0.45) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL20624944 | 0.70 | PABPC1 (0.51) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL21987642 | 0.70 | PABPC1 (0.47) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL8637708 | 0.70 | GAA (0.50) | PABPC1CTDSP1GAAALDH1A1TMEM97 | |
| SCHEMBL1487109 | 0.69 | PABPC1 (0.53) | PABPC1CTDSP1GAAALDH1A1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | claimed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | claimed |
| CN-119997958-A | Treatment of ejection fraction retention heart failure with guanethidine and guanacol | M2SP有限责任公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | UNIVERSITAT AUTÒNOMA DE BARCELONA (ES) | 2023-05-11 | — | — | US | disclosed |
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021191417-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2021-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147129-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | SNCA, PARK7, PRNP | SLC6A2 208/4885PABPC1 1022/4885CTDSP1 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.